Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1986 |
| IPO Date | Mar 3, 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 435 |
| CEO | Charles Gayer |
Contact Details
Address: 4505 Emperor Boulevard, Suite 200 Durham, North Carolina 27703 United States | |
| Phone | 919 859 1302 |
| Website | biocryst.com |
Stock Details
| Ticker Symbol | BCRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882796 |
| CUSIP Number | 09058V103 |
| ISIN Number | US09058V1035 |
| Employer ID | 62-1413174 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Charles K. Gayer | Chief Executive Officer, President and Director |
| Alane P. Barnes | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Babar Ghias | Chief Financial Officer and Head of Corporate Development |
| John Ruesch | Chief Technical Operations Officer |
| Nick Wilder | Manager of Investor Relations |
| Stephanie Angelini | Chief People Officer and Chief Communications Officer |
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer |
| Jinky Ang Rosselli | Chief Data Innovation Officer |
| Philip George | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 144 | Filing |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Jan 23, 2026 | 8-K/A | [Amend] Current report |
| Jan 23, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 8-K | Current Report |
| Dec 22, 2025 | 144 | Filing |